miércoles, 5 de septiembre de 2012

Pharma Mergers Stories

The first half of 2012 has seen $44.6bn of global biopharma takeover activity, a 29% increase over a year ago. However, the number of deals done has remained fairly constant – backing up the view that more cash is increasingly being thrown at the R&D productivity problem.

But while individual deal values are creeping up, and replenishing big pharma revenues lost to generic competition is a clear driver, anything that could be described as a takeover frenzy still seems some way off, EvaluatePharma data show. Last year’s first half also gave hopes that M&A action was stepping up but these failed to materialise, and – unless the second half of 2012 lives up to the billing of the first – bullish biotech investors might find that the status quo has largely prevailed by the time the year is out (see table below).

So far this year the combined deal values are already equivalent to some 82% of the total done during the whole of 2011. But last year was heavily skewed in favour of the first half too, in which 87 deals were done for a combined $34.6bn, the subsequent second half slow down resulted in the less impressive 29% year-over-year increase. (Más)

Pasado...

Slide: F.Comas/Curso Postgrado Mktg.Farmacéutico Facultad Farmacia
Universidad Central de Venezuela (UCV)
(Click sobre imagen para ampliar)


Ver

Presente



Publicar un comentario